Healthcare Press

FDA Approves Danicopan as Add-On Therapy for Hemolysis Treatment

  • 📰 Medscape
  • ⏱ Reading Time:
  • 24 sec. here
  • 12 min. at publisher
  • 📊 Quality Score:
  • News: 48%
  • Publisher: 55%

Health News

FDA,Danicopan,Add-On Therapy

The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab orPNH is a rare blood disorder affecting 1-10 individuals per million. The condition, which eliminates red blood cells and leads to blood clots and impaired bone marrow function, can cause life-threateningRavulizumab and eculizumab, also both made by AstraZeneca, inhibit the destruction of red blood cells. However, 10%-20% of patients treated with the antibody infusions experience significant extravascular hemolysis, in which these surviving red blood cells are eliminated by the spleen and liver. Extravascular hemolysis can lead to ongoing anemia, which can lead patients to require blood transfusions. Danicopan, an investigational, first-in-class, oral complement factor D inhibitor, is designed to control intravascular hemolysis and prevent extravascular hemolysis

The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab orPNH is a rare blood disorder affecting 1-10 individuals per million. The condition, which eliminates red blood cells and leads to blood clots and impaired bone marrow function, can cause life-threateningRavulizumab and eculizumab, also both made by AstraZeneca, inhibit the destruction of red blood cells.

However, 10%-20% of patients treated with the antibody infusions experience significant extravascular hemolysis, in which these surviving red blood cells are eliminated by the spleen and liver. Extravascular hemolysis can lead to ongoing anemia, which can lead patients to require blood transfusions. Danicopan, an investigational, first-in-class, oral complement factor D inhibitor, is designed to control intravascular hemolysis and prevent extravascular hemolysi

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA OKs Danicopan Add-On for Extravascular Hemolysis in Adults With PNHA tablet has been approved for a common complication during treatment for a rare blood disorder.
Source: Medscape - 🏆 386. / 55 Read more »

Yogurt Makers Can Make Limited Claims About Type 2 Diabetes Prevention: FDAYogurt makers can now make limited claims about the food's power to help prevent type 2 diabetes, the U.S. Food and Drug Administration says.
Source: MedicineNet - 🏆 575. / 51 Read more »

FDA Warns of Toxic Lead in Cinnamon ProductsThe U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead.
Source: MedicineNet - 🏆 575. / 51 Read more »